Summary
The linear and predictable pharmacokinetic properties of the histamine H1-receptor antagonist levocabastine make it particularly suitable for intranasal or ocular treatment of allergic rhinoconjunctivitis. Peak plasma concentrations (Cmax) occur within 1 to 2 hours of administration of single doses of levocabastine nasal spray and eye drops (0.2mg and 0.04mg, respectively). Drug absorption is incomplete after intranasal and ocular administration, with systemic availability ranging from 60 to 80% for levocabastine nasal spray and from 30 to 60% for the eye drops. However, as the amount of levocabastine applied intranasally and ocularly is small, the levocabastine plasma concentrations achieved are extremely low, with Cmax values in the ranges 1.4 to 2.2 μ/L and 0.26 to 0.29 μg/L for intranasal and ocular administration, respectively.
Pharmacokinetic-pharmacodynamic modelling has indicated that the clinical benefits of levocabastine are predominantly mediated through local antihistaminic effects, although some systemic activity may contribute to the therapeutic efficacy of levocabastine nasal spray during long term use.
Levocabastine undergoes minimal hepatic metabolism, i.e. ester glucuronidation, and is predominantly cleared by the kidneys. Approximately 70% of parent drug is recovered unchanged in the urine. Plasma protein binding is approximately 55% and the potential for drug interactions involving binding site displacement is negligible. Furthermore, the pharmacokinetics of this agent do not appear to be influenced by either age or gender. Levocabastine nasal spray and eye drops may thus be considered suitable for the treatment of allergic rhinoconjunctivitis in a wide patient population.
Similar content being viewed by others
References
Weeke ER. Epidemiology of hay fever and perennial allergic rhinitis. Monogr Allergy 1987; 21: 1–20
White MV. The role of histamine in allergic diseases. J Allergy Clin Immunol 1990; 86: 599–605
Badhwar AK, Druce HM. Allergic rhinitis. Clin Allergy 1992; 76: 789–803
Dechant KL, Goa KL. Levocabastine: a review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis. Drugs 1991; 41: 202–24
Vanden Bussche G. Levocabastine hydrochloride. Drugs Future 1986; 11: 841–3
Awouters F, Niemegeers C, Jansen T, et al. Levocabastine: Pharmacological profile of a highly effective inhibitor of allergic reactions. Agents Actions 1992; 35: 12–8
Van Wauwe JP. Animal pharmacology of levocabastine: a new type of H1-antihistamine well-suited for topical application. In: Mygind N, Naclerio RM, editors. Rhinoconjunctivitis: new perspectives in topical treatment of seasonal allergic rhinitis. Proceedings of the XIIIth International Congress of Allergology and Clinical Immunology, 1988 Oct; Montreux: Hogrefe & Huber Publishers, 1989: 27–34
Pécoud A, Zuber P, Kolly M. Effect of a new selective H1 receptor antagonist (levocabastine) in a nasal and conjunctival provocation test. Int Arch Allergy Appl Immunol 1987; 82: 541–3
Abelson MB, Smith LM. Levocabastine: evaluation in the histamine and compound 48/80 models of ocular allergy in humans. Ophthalmology 1988; 95: 1494–7
Palma-Carlos AG, Palma-Carlos ML, Rombaut N. The effect of levocabastine nasal spray in nasal provocation tests. Int J Clin Pharmacol Res 1988; 8: 25–30
Rimås M, Kjellman N-IM, Blychert L-O, et al. Topical levocabastine protects better than sodium cromoglycate and placebo in conjunctival provocation tests. Allergy 1990; 45: 18–21
Stokes TC, Feinberg G. Rapid onset of levocabastine eye-drops in histamine-induced conjunctivitis. Clin Exp Allergy 1993; 23: 791–4
Azevedo M, Castel-Branco MG, Ferrez Oliveira J, et al. Double-blind comparison of levocabastine eye drops with sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis. Clin Exp Allergy 1991; 21: 689–94
Palma-Carlos AG, Chieira C, Conde TA, et al. Double-blind comparison of levocabastine nasal spray with sodium cromoglycate nasal spray in the treatment of seasonal allergic rhinitis. Ann Allergy 1991; 67: 394–8
Schata M, Jorde W, Richarz-Barthauer U. Levocabastine nasal spray better than sodium cromoglycate and placebo in the topical treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1991; 87: 873–8
Davies BH, Mullins J. Topical levocabastine is more effective than sodium cromoglycate for the prophylaxis and treatment of seasonal allergic conjunctivitis. Allergy 1993; 48: 519–24
The Livostin Study Group. A comparison of topical levocabastine and oral terfenadine in the treatment of allergic rhinoconjunctivitis. Allergy 1993; 48: 530–4
Bahmer FA, Ruprecht KW. Safety and efficacy of topical levocabastine compared with oral terfenadine. Ann Allergy 1994; 72: 429–34
Søhoel P, Freng BA, Kramer J, et al. Topical levocabastine compared with oral terfenadine for the treatment of seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 1993; 92: 73–81
The Swedish GP Allergy Team. Topical levocabastine compared with oral loratadine for the treatment of seasonal allergic rhinoconjunctivitis. Allergy 1994; 49: 611–5
Bende M, Pipkorn U. Topical levocabastine, a selective H1-antagonist in seasonal allergic rhinoconjunctivitis. Allergy 1987; 42: 512–5
Woestenborghs R, Geuens I, Lenoir H, et al. On the selectivity of some recently developed RIAs. In: Reid E, Wilson ID, editors. Methodological surveys in biochemistry and analysis. Vol. 20. Cambridge, UK: Royal Society of Chemistry, 1990: 241–6
Heykants J, Van Peer A, Woestenborghs R, et al. The pharmacokinetics and bioavailability of levocabastine (R 50547) as studied after single intravenous and oral dosing and after multiple oral dosing in healthy subjects. Unpublished report N 40324, Janssen Research Foundation, Beerse, 1984
Heykants J, Van Peer A, Woestenborghs R, et al. The absorption and plasma levels of levocabastine (R 50547) after single and multiple intranasal application of the nose spray formulation to healthy subjects. Unpublished report N 40325, Janssen Research Foundation, Beerse, 1984
Van de Velde V, Van Peer A, Woestenborghs R, et al. Comparative bioavailability of a levocabastine suspension and solution after nasal administration to healthy volunteers. Unpublished report N 62440, Janssen Research Foundation, Beerse, 1988
Heykants J, Van Peer A, Woestenborghs R, et al. The absorption and plasma levels of levocabastine (R 50547) in healthy subjects after single and multiple instillation of the eye-drop formulation. Unpublished report N 40329, Janssen Research Foundation, Beerse, 1985
Van de Velde V, Van Peer A, Woestenborghs R, et al. Bioavailability and bioequivalence of a levocabastine suspension and solution after ophthalmic administration. Unpublished report N 59216, Janssen Research Foundation, Beerse, 1987
Lücker PW, Adolph S. Medical report on the results obtained from a study for evaluating the rate of nasal absorption comparing healthy volunteers and patients with rhinitis. Unpublished report N 62426, Janssen Research Foundation, Beerse, 1986
Weinberg E. Levocabastine nasal spray in the treatment of rhinitis in asthmatic children: a double-blind comparison with placebo. Unpublished report N 62438, Janssen Research Foundation, Beerse, 1988
de Corres F, Diaz-Pardo L. Double-blind comparison of levocabastine nasal spray with sodium cromoglycate in the topical treatment of seasonal allergic rhinitis. Unpublished report N 62501, Janssen Research Foundation, Beerse, 1988
Lücker PW, Adolph S. Medical report on the results obtained from a study for evaluating the rate of conjunctival absorption comparing healthy volunteers and patients with conjunctivitis. Unpublished report N 62425, Janssen Research Foundation, Beerse, 1986b
Heykants JJP, Snoeck E, Awouters F, et al. Antihistamines. In: Van Boxtel CJ, Holford NHG, Danhof M, editors. The in vivo study of drug action. Amsterdam: Elsevier Science Publishers 1992: 337–56
Harvey RP, Schocket AL. The effect of H1-blockade on cutaneous histamine response in man. J Allergy Clin Immunol 1980; 65: 136–9
Walker J, Howarth P, Hamilton I, et al. A placebo-controlled trial of the therapeutic value of levocabastine eye drops used as required in the treatment of seasonal allergic conjunctivitis. Unpublished report, N 62497, Janssen Research Foundation, Beerse, 1988
Heykants J, Van Peer A, Woestenborghs R, et al. Pharmacokinetics and bioavailability of levocabastine (R 50547) in man. Arch Int Pharmacodyn Ther 1985; 274: 329–30
Prandota J. Clinical pharmacokinetics of changes in drug elimination in children. Dev Pharmacol Ther 1985; 8: 311–28
Zazgornik J, Huang ML, Van Peer A, et al. Pharmacokinetics of orally administered levocabastine in patients with renal insufficiency. J Clin Pharmacol 1993; 33: 1214–8
Wihl JÅ, Rudblad S, Kjellén H, Blychert LA. Levocabastine eye drops versus sodium cromoglycate in seasonal allergic conjunctivitis. Clin Exp Allergy 1991; 21 Suppl. 2: 37–8
Kemp JP. Antihistamines. Is there anything safe to prescribe? Ann Allergy 1992; 69: 276–80
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Heykants, J., Van Peer, A., Van de Velde, V. et al. The Pharmacokinetic Properties of Topical Levocabastine. Clin-Pharmacokinet 29, 221–230 (1995). https://doi.org/10.2165/00003088-199529040-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199529040-00002